Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.
Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, Wauters E, Pomella V, Verbandt S, Busschaert P, Bassez A, Franken A, Bempt MV, Xiong J, Weynand B, van Herck Y, Antoranz A, Bosisio FM, Thienpont B, Floris G, Vergote I, Smeets A, Tejpar S, Lambrechts D. Qian J, et al. Among authors: vergote i. Cell Res. 2020 Sep;30(9):745-762. doi: 10.1038/s41422-020-0355-0. Epub 2020 Jun 19. Cell Res. 2020. PMID: 32561858 Free PMC article.
Genetic changes in nonepithelial ovarian cancer.
Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Van Nieuwenhuysen E, et al. Among authors: vergote i. Expert Rev Anticancer Ther. 2013 Jul;13(7):871-82. doi: 10.1586/14737140.2013.811174. Expert Rev Anticancer Ther. 2013. PMID: 23875665 Review.
Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.
Schrauwen S, Coenegrachts L, Depreeuw J, Luyten C, Verbist G, Debruyne D, Vergote I, Lambrechts D, Amant F. Schrauwen S, et al. Among authors: vergote i. Int J Gynecol Cancer. 2015 Mar;25(3):363-71. doi: 10.1097/IGC.0000000000000363. Int J Gynecol Cancer. 2015. PMID: 25695543
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Among authors: vergote i. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Depreeuw J, Hermans E, Schrauwen S, Annibali D, Coenegrachts L, Thomas D, Luyckx M, Gutierrez-Roelens I, Debruyne D, Konings K, Moerman P, Vergote I, Lambrechts D, Amant F. Depreeuw J, et al. Among authors: vergote i. Gynecol Oncol. 2015 Oct;139(1):118-26. doi: 10.1016/j.ygyno.2015.07.104. Epub 2015 Jul 29. Gynecol Oncol. 2015. PMID: 26232337
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A. Despierre E, et al. Among authors: vergote i. Target Oncol. 2016 Jun;11(3):429. doi: 10.1007/s11523-016-0433-x. Target Oncol. 2016. PMID: 27056749 No abstract available.
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.
Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A, Timmerman D, Lambrechts D, Vergote I. Vanderstichele A, et al. Among authors: vergote i. Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. Epub 2016 Nov 14. Clin Cancer Res. 2017. PMID: 27852697
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D. Kreuzinger C, et al. Among authors: vergote i. Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2. Clin Cancer Res. 2017. PMID: 28972047 Free article.
874 results